Predictors of distress and quality of life in patients undergoing cancer therapy: impact of treatment type and decisional role
- 25 June 2009
- journal article
- research article
- Published by Wiley in Psycho‐Oncology
- Vol. 19 (6), 606-616
- https://doi.org/10.1002/pon.1590
Abstract
Purpose: The purpose of this secondary investigation was to examine the impact of the type of treatment received and the perceived role in treatment decision making in predicting distress and cancer-specific quality of life in patients newly diagnosed with breast or prostate cancer. Method: Participants included 1057 newly diagnosed breast and prostate cancer patients from four Canadian cancer centers who partook in a randomized controlled trial examining the utility of providing patients with an audio-recording of their treatment planning consultation. A MANCOVA was performed to predict distress and cancer-specific quality of life at 12 weeks post-consultation based on control variables (patient age, education, residence, tumor size (breast sample), gleason score (prostate sample), and receipt of an initial treatment consultation recording), predictor variables (treatment type—chemotherapy, hormone therapy, radiation therapy; decisional role—active, collaborative, passive), and interactions between these predictors. Results: Women who received chemotherapy and reported having played a more passive role in treatment decision making had significantly greater distress and lower cancer-specific quality of life at 12-week post-consultation. There were no statistically significant predictors of these outcomes identified for men with prostate cancer. Conclusion: Receipt of chemotherapy places women with breast cancer at risk for distress and reduced quality of life, but only for the subset of women who report playing a passive role in treatment decision making. Prospective, longitudinal studies are needed to confirm the present findings and to explicate the antecedents, composition, and consequences of the ‘passive’ decisional role during the treatment phase of the cancer trajectory. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 34 references indexed in Scilit:
- Course of the Fatigue Dimension "Activity Level" and the Interference of Fatigue With Daily Living Activities for Patients With Breast Cancer Receiving Adjuvant ChemotherapyCancer Nursing, 2006
- Side‐effects of treatments for locally advanced prostate cancerBJU International, 2005
- Use of a Case Definition Approach to Identify Cancer-Related Fatigue in Women Undergoing Adjuvant Therapy for Breast CancerJournal of Clinical Oncology, 2005
- Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancerCurrent Urology Reports, 2004
- Evolution of breast cancer treatments: current options and quality-of-life considerationsEuropean Journal of Oncology Nursing, 2004
- Quality of life after treatment for prostate cancerCurrent Urology Reports, 2003
- Cognitive Dysfunction and Chemotherapy: Neuropsychological Findings in PerspectiveClinical Breast Cancer, 2002
- The impact of endocrine therapy on patients with breast cancer: a review of the literatureThe Breast, 2002
- The association of treatment‐related symptoms with quality‐of‐life outcomes for localized prostate carcinoma patientsCancer, 2002
- Is Fatigue a Long-term Side Effect of Breast Cancer Treatment?Cancer Control, 1999